Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
- 1 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 69 (10), 2053-2061
- https://doi.org/10.1007/s00262-020-02611-x
Abstract
Objective To explore the programmed death-ligand 1 (PD-L1) expression in varied subtypes of pituitary neuroendocrine tumors with assessment of their clinical behavior at diagnosis and follow-up. Methods We conducted a retrospective monocentric study, including all patients operated in the Academic Hospital of Angers (France) for a pituitary neuroendocrine tumor between 2012 and 2018. PDL-1 immunostaining was performed using a European Conformity-In Vitro Diagnostic-labeled anti-PDL1 antibody (clone 22C3). PD-L1 immunostaining was evaluated as the percentage of tumor cells showing positive membrane staining, into four grades: grade 0 = < 1%, grade 1 = 1 to 5%, grade 2 = 6 to 49% and grade 3 = >= 50%. PD-L1 expression was compared with tumor features (secretion, proliferation, invasion) and outcome. Results The study included 139 pituitary neuroendocrine tumors, including 84 (60%) nonfunctioning adenomas. Twenty-five pituitary neuroendocrine tumors were PD-L1 positive (18%), including 3 grade 3, 8 grade 2 and 14 grade 1. PD-L1 expression was not different between functioning and nonfunctioning adenomas (p = 0.26). Among 16 tumors with proliferative markers (Ki-67 >= 3% and p53 positive), only one was PD-L1 positive. Conclusion In our series, PD-L1 was expressed in a rather small proportion of PitNET (18%), and this immune marker was not associated with any biological characteristic or behavior of the pituitary tumors. Thus, PD-L1 staining may be necessary before considering PD-L1 blockage in pituitary neuroendocrine tumors, in case of therapeutic impasse.This publication has 27 references indexed in Scilit:
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015Neuro-Oncology, 2018
- Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and NivolumabJournal of Clinical Endocrinology & Metabolism, 2018
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomasActa Endocrinologica, 2018
- Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered ClassificationJournal of Clinical Endocrinology & Metabolism, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaThe New England Journal of Medicine, 2017
- Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK CentersJournal of Clinical Endocrinology & Metabolism, 2017
- Diagnosis and Treatment of Pituitary AdenomasJAMA, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2015